Inducible Ik1 Isoform Expression

Cloning and cell line generation was performed as described previously [29 (link)]. Briefly, full length Ikaros isoform (Ik1) with IRES-GFP and an empty vector IRES-GFP control were cloned into the TET-inducible expression vector pLVX-TRE3G-IRES (Takara Bio, San Jose, CA, USA) and transduced into B-ALL cells expressing TET activator pLVX-EF1a-Tet3G (Takara Bio, San Jose, CA, USA). Expression of wild-type IK1 and GFP control samples was induced with the addition of 1 ug/mL doxycycline, a TET analog.

Free full text: Click here

Kogut S., Paculova H., Rodriguez P., Boyd J., Richman A., Palaria A., Schjerven H, & Frietze S. (2022). Ikaros Regulates microRNA Networks in Acute Lymphoblastic Leukemia. Epigenomes, 6(4), 37.

Publication 2022

pLVX-TRE3G-IRES pLVX-EF1a-Tet3G

Cell line Cells Doxycycline Ires Isoform Vector

Corresponding Organization : UCSF Helen Diller Family Comprehensive Cancer Center

Top 5 similar protocols

Variable analysis

independent variables

Expression of wild-type IK1
Expression of GFP control

dependent variables

Not explicitly mentioned

control variables

Addition of 1 ug/mL doxycycline, a TET analog, to induce expression

controls

Positive control: Expression of wild-type IK1
Negative control: Expression of GFP control

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!